Rebinyn Approval for Hemophilia B Expanded to Include Routine Prophylaxis
Rebinyn is a recombinant DNA-derived coagulation Factor IX concentrate with an extended half-life.
Bleeding Disorders
Millennials With Hemophilia: Attitudes and Expectations From Treatment
Researchers sought to determine the attitudes and expectations of patients with hemophilia belonging to Generation Y regarding their treatment.
Once-Weekly Efanesoctocog Alfa Prevents Bleeding Episodes in Hemophilia A Trial
The phase 3 XTEND-1 study evaluated efanesoctocog alfa in 159 patients with severe hemophilia A who were previously treated with factor VIII replacement therapy.
Novel Antithrombotic Fast Tracked for Noncardioembolic Ischemic Stroke
The Company is currently evaluating asundexian as monotherapy or in combination with antiplatelet therapy in the PACIFIC phase 2 clinical trial program.
Vonvendi Approved for Severe Type 3 von Willebrand Disease
Results showed the median ABR for all bleeds was reduced by 54.7%.
Durable Response Observed With Gene Therapy for Hemophilia A
The phase 3 GENEr8-1 study evaluated valoctocogene roxaparvovec in adults with severe hemophilia and residual FVIII levels less than or equal to 1 IU/dL.
FDA Clears System That Allows for Remote Endoscopy Procedures
PillCam SB3 @HOME offers a telehealth option for direct visualization and monitoring of the small intestine.
FDA Issues Safety Alert Regarding Use of Hydroxyethyl Starch Products
There are currently 4 FDA-approved hydroxyethyl starch products on the market.
Hemophilia: What Your Patients Need to Know
Hemophilia is a bleeding disorder caused by a genetic mutation that is often inherited. Patients who are at risk and parents or caregivers of children at risk of hemophilia may need additional education about what causes hemophilia and how it is diagnosed and treated.
FDA Identifies Most Needed Meds to Address Urgent Medical Conditions
This action was in response to an executive order issued on August 6, 2020 aimed at protecting the public against outbreaks of emerging diseases and chemical, biological, radiological, and nuclear threats.
- Loading...
Loading...
Loading... 
Loading...